Mesoblast

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

% Price Oscillator

Score

-3.1

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 15 23.9 0.20% 0.25% 3.5% -7.7% -82.4%
SHORT 15 26.7 0.20% 0.25% 2.7% -9.0% -100.6%

Summary

Technical Analysis


The Percentage Price Oscillator (PPO) is a momentum oscillator that measures the difference between two moving averages as a percentage of the larger moving average.

Calculation: Percentage Price Oscillator (PPO):
1) PPO Line: {(12-day EMA - 26-day EMA)/26-day EMA} x 100;
2) Signal Line: 9-day EMA of PPO;
3) Histogram: PPO - Signal Line;


PROFILE: Mesoblast (MSB.AX)


Stock Exchange: ASX
Company: Mesoblast
Ticker Codes: | MSB.AX | ASX:MSB |

About Mesoblast (ASX:MSB):

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Top 10:

% Price Oscillator

Download
Company Close Change(%) Volume Value Signal
EML Emerchants 4.35 13.6 7,106,370 -0.63 BEARISH
APX Appen 22.66 5.9 1,026,466 -0.88 BEARISH
NMT Neometals 0.2 5.3 241,577 -0.42 BEARISH
BSE BSE 0.22 4.9 77,053 -3.42 BEARISH
BSA Broadcast Services Australia 0.4 3.9 157,046 -2.14 BEARISH
KAR Karoon Gas Australia 1.1 3.8 5,014,070 -2.38 BEARISH
SMX Sms Management & Technology 0.3 3.4 1,266 -1.54 BEARISH
IPD Impedimed 0.17 3.1 1,756,283 -1.52 BEARISH
PME Pro Medicus 26.36 3 303,033 -4.22 BEARISH
ISD Isentia 0.35 2.9 107,927 -3.12 BEARISH